Printer Friendly

UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.

UCB has announced positive top-line results for signs and symptoms from two new phase III studies for CIMZIA(TM) (certolizumab pegol), the first Fab' fragment anti-TNF (Tumor Necrosis Factor), in the treatment of rheumatoid arthritis. In both the RAPID 1 (027) and RAPID 2 (050) studies CIMZIA(TM), in combination with methotrexate, demonstrated superiority to placebo, and a statistically significant improvement in the signs and symptoms of rheumatoid arthritis as measured by all American College of Rheumatology (ACR) scores: ACR20, 50, and 70. Further details on the results from the RAPID studies, including data on the prevention of structural damage, will be released during the first quarter of 2007.

UCB also provided an update on the status of the US approval of CIMZIATM in the treatment of Crohn's disease. UCB has received a Complete Response Letter from the United States Food and Drug Administration (FDA) requesting additional information and clarification on data submitted in its Biologics License Application (BLA) for the approval of CIMZIATM in Crohn's disease.

"We have absolute confidence in both the efficacy and tolerability profile of CIMZIATM, and in gaining US approval" said Melanie Lee, executive vice president R&D for UCB. "We are extremely pleased by the rheumatoid arthritis results and will work closely with the FDA to clarify any questions that they have, or may have, regarding CIMZIATM for the treatment of Crohn's disease and rheumatoid arthritis."

About UCB

UCB is a global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy / respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in 40 countries, it has worldwide headquarters located in Brussels, Belgium, UCB is listed on the Euronext Brussels Exchange.

For more information, visit http://www.ucb-group.com.
COPYRIGHT 2007 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Feb 1, 2007
Words:313
Previous Article:LIPOXEN SIGNS $75MIL PACT TO DEVELOP BLOOD CLOTTING FACTORS.
Next Article:APPROVAL FOR U.K. CLINICAL TRIAL FOR REOLYSIN.


Related Articles
Betaseron bulletin.
PHASE IIB MBI 594AN STUDY VALIDATES ANTI-ACNE PROPERTIES.
INCLONE/UCB TO DEVELOP/COMMERCIALIZE CDP-791.
Ono Pharmaceutical Announces Changes in Investigational AIDS Drug Development Program.
BASILEA REPORTS 92% CLINICAL CURE RATES FOR CEFTOBIPROLE.
FDA CLEARS BIOMS MEDICAL FOR PHASE III MULTIPLE SCLEROSIS.
UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF CIMZIA.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters